Alnylam Pharmaceuticals, Inc.
Methods of treating transthyretin (TTR) mediated amyloidosis

Last updated:

Abstract:

Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.

Status:
Grant
Type:

Utility

Filling date:

3 Aug 2018

Issue date:

3 Aug 2021